Studie COLCOT

Interv Akut Kardiol. 2021;20(1):44-45

The COLCOT trial

Lenka Špinarová, Jindřich Špinar, Jiří Vítovec: I. interní kardioangiologická klinika LF MU a FN u sv. Anny, Brno

The COLCOT trial evaluated the administration of colchicine versus placebo in patients after myocardial infarction. The trial was conducted based on a clinical hypothesis that inflammatory processes may play a role in the process of atherogenesis and its complications. The primary composite endpoint was: time to cardiovascular death, cardiac arrest, myocardial infarction, stroke, urgent hospitalization for angina pectoris leading to revascularization. A primary endpoint event occurred in 5.5 % of the patients in the colchicine group as compared with 7.1 % of those in the placebo group (p < 0.02). The overall mortality did not differ between the groups. Colchicine tolerance was comparable to that of the placebo, including the incidence of diarrhoea.